In the current grant we will investigate the metabolic reasons for variations in acute nitrogen responses to growth hormone, and study mechanisms of adaptation to growth hormone treatment which cause a return to pretreatment growth rates on chronic growth hormone treatment. Specifically, we plan: 1) To quantify the contribution of body protein turnover to resting, postprandial, and total daily energy expenditure in mid-childhood and test the hypothesis that these relationships are altered in children with short stature. 2) To measure short childrens' sensitivity to insulin and test the hypothesis that nitrogen retention to acute growth hormone challenge is directly proportional to glucose and amino acid sensitivity to insulin. 3) To determine the relationships between nitrogen kinetics, amino acid oxidation, and daily energy expenditure in short children treated with growth hormone on a long-term basis and test the hypotheses that: a. Protein turnover, protein synthesis, and energy expenditure increase in a commensurate fashion while amino acid oxidation declines proportionately during the period of rapid growth. b. Total daily energy expenditure declines and protein turnover and synthesis represent a reduced fraction of daily energy expenditure in those children whose height velocity declines on continued treatment. c. Development of attenuated height velocity response to continued treatment with recombinant human growth hormone is associated with the degree of resistance developed to insulin's actions on glucose and amino acid metabolism.

Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Umayahara, Y; Billiard, J; Ji, C et al. (1999) CCAAT/enhancer-binding protein delta is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts. J Biol Chem 274:10609-17
Umayahara, Y; Ji, C; Centrella, M et al. (1997) CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts. Identification of a novel cyclic AMP signaling pathway in bone. J Biol Chem 272:31793-800
Mittanck, D W; Kim, S W; Rotwein, P (1997) Essential promoter elements are located within the 5' untranslated region of human insulin-like growth factor-I exon I. Mol Cell Endocrinol 126:153-63
Pike, L J; Casey, L (1996) Localization and turnover of phosphatidylinositol 4,5-bisphosphate in caveolin-enriched membrane domains. J Biol Chem 271:26453-6
Rotwein, P; Bichell, D P; Kikuchi, K (1993) Multifactorial regulation of IGF-I gene expression. Mol Reprod Dev 35:358-63;discussion 363-4
Bichell, D P; Rotwein, P; McCarthy, T L (1993) Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblast cultures: evidence for transcriptional control. Endocrinology 133:1020-8
Daughaday, W H; Trivedi, B (1992) Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum. J Clin Endocrinol Metab 75:641-5
Daughaday, W H; Trivedi, B (1992) Measurement of derivatives of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 75:110-5
Kim, S W; Lajara, R; Rotwein, P (1991) Structure and function of a human insulin-like growth factor-I gene promoter. Mol Endocrinol 5:1964-72
Daughaday, W H; Trivedi, B (1991) Clinical aspects of GH binding proteins. Acta Endocrinol (Copenh) 124 Suppl 2:27-32

Showing the most recent 10 out of 12 publications